Search the Newsreel

Scotts Miracle-Gro’s (SMG) Margin Squeeze: Does a Steady Dividend Mask Deeper Profitability Strains?

Stifel raises Scotts Miracle-Gro stock price target on earnings upside

Miramar Hotel Sets August Board Meeting to Approve Interim Results and Dividend

MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA

This article provides a basic overview of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) and directs users to financial data on TradingView. It indicates that the market is closed with no trades and points to various financial sections like statements, statistics, dividends, and earnings. The article …

Admiral Group plc Revenue Breakdown – LSE:ADM

Tangible book value per share of MIRA Pharmaceuticals, Inc. – MUN:K6S

This article provides the tangible book value per share for MIRA Pharmaceuticals, Inc. (MUN:K6S) as listed on the Munich Stock Exchange. It indicates that the market was closed at the time of publication and no trades had occurred. The information is presented within a …

Mira Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Mira Pharmaceuticals (MIRA) announced that it received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company's stock has traded below $1.00 for 30 consecutive business days, and it now has 180 days until January 25, 2027, to regain …

The Scotts Miracle-Gro Company 2026 Q3 - Results - Earnings Call Presentation (NYSE:SMG) 2026-07-31

The Scotts Miracle-Gro Company Q3 2026 Earnings Call Summary - Moby Strategic Shift and Operational Progress Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …

MIRA Pharmaceuticals advances non-opioid pain and obesity drug candidates toward IND-enabling studies.

MIRA Pharmaceuticals has successfully advanced its two primary drug candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction disorders, through key preclinical development phases. These stages included optimizing formulation, manufacturing, and conducting exploratory toxicology studies. The company is now preparing to …

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals announced significant progress in the development of its two lead preclinical programs, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders. The company has completed 7-day toxicology and pharmacokinetic studies, alongside formulation optimization, CMC activities, and manufacturing development. These …

MIRA's Two Oral Drug Candidates Finish Dosing in Rats and Dogs

MIRA Pharmaceuticals announced that its two lead preclinical programs, MIRA-55 (for chronic inflammatory pain) and SKNY-1 (for obesity and addiction-related disorders), have completed the dosing phase of exploratory 7-day toxicology studies in rats and dogs. This advancement, alongside formulation optimization and manufacturing activities, moves …

MIRA Pharmaceuticals completes toxicology studies for two candidates

MIRA Pharmaceuticals (NASDAQ:MIRA) announced the completion of 7-day toxicology and pharmacokinetic studies for its two preclinical drug candidates, MIRA-55 and SKNY-1. MIRA-55 is being developed for chronic inflammatory pain, while SKNY-1 is for obesity and addiction-related disorders. The company is advancing both programs through …

Miramar Resources Insiders Lose Out As Stock Sinks To AU$0.002

Scotts Miracle Gro (SMG) Stock Price Reflects Debt Fears Over Margin Gains

Regina Miracle Details Planned Re-Appointment and Audit Fee for PwC

ScottsMiracle-Gro Announces Speakers and Other Details for its Investor Day on August 4, 2026

The Scotts Miracle-Gro Company (NYSE: SMG) has announced details for its Investor Day, scheduled for Tuesday, August 4, 2026, at the New York Stock Exchange. The event will feature presentations and Q&A sessions with key executives, focusing on SMG's 2.0 growth strategy, capital allocation, …

The Scotts Miracle Gro Co (SMG) Q3 2026 Earnings Call Highlights: Strong Sales Growth Amid Cost ...

This article first appeared on GuruFocus. Total Company Net Sales: Increased 1% to $1.17 billion in Q3; year-to-date increased 2% to $2.99 billion. US Consumer Business Net Sales: Increased 2% year-to-date to $2.74 billion. Branded Product Sales Growth: Up 4.5% year-to-date. Gross Margin Rate: …

Scotts Miracle-Gro Is Positioned for Long-Term US Gardening Growth

Scotts Miracle-Gro, a leading company in the US consumer lawn and gardening market, is positioned for long-term growth. The company provides a wide range of products for lawncare and gardening. This report highlights their business strategy and outlook, despite recent news of the CEO …

Scotts Miracle-Gro (SMG) Tops Q3 Earnings Estimates

Scotts Miracle-Gro (SMG) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.53 per share. This compares to earnings of $2.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Scotts (SMG) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Scotts Miracle-Gro (SMG) reported revenue of $1.17 billion, down 1.3% over the same period last year. EPS came in at $2.82, compared to $2.59 in the year-ago quarter. The reported revenue represents a surprise of -0.17% over the …

ScottsMiracle-Gro Reports Third Quarter Results; Updates Full-Year Outlook Reflecting Accelerated EPS Growth

Scotts Miracle-Gro Company (The) Company raises its full-year non-GAAP adjusted EPS from continuing operations guidance to $4.30 to $4.45, up from the prior guidance of $4.15 to $4.35 MARYSVILLE, Ohio, July 29, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading …

Mira Pharmaceuticals Inc (MIRA) Institutional Confidence

This article provides an analysis of Mira Pharmaceuticals Inc (MIRA) institutional confidence score, which currently stands at 3.00 with no change since the previous score. It details the shares held by various institutional investors, including Bay Shore Trust, McNulty (Brian Patrick), and Geode Capital …

Scotts Miracle-Gro: Post-Earnings Sell-Off Is A Buying Opportunity (NYSE:SMG)

Scotts Miracle-Gro (NYSE:SMG) Announces Quarterly Earnings Results, Beats Expectations By $0.34 EPS

Scotts Miracle-Gro declares $0.66 dividend

* Scotts Miracle-Gro (SMG [https://seekingalpha.com/symbol/SMG]) declares $0.66/share quarterly dividend [https://seekingalpha.com/pr/20598398-the-scotts-miracle-gro-company-announces-quarterly-dividend-payment], in line with previous. * Forward yield [https://seekingalpha.com/symbol/SMG/dividends/yield?source=news_bullet] 3.6% * Payable Sept. 4; for shareholders of record Aug. 21; ex-div Aug. 21. * See SMG Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/SMG/dividends?source=news_bullet] MORE …

The Scotts Miracle-Gro Company Announces Quarterly Dividend Payment

The Scotts Miracle-Gro Company (NYSE: SMG) has announced that its Board of Directors approved a cash dividend payment of $0.66 per share. The dividend is scheduled to be paid on September 4, 2026, to shareholders of record as of August 21, 2026. The company …

Regina Miracle International (Holdings) Limited Revenue Breakdown – HKEX:2199

Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis

Mira Pharmaceuticals Inc (MIRA) currently holds a financial score of 7.04, ranking 155 out of 386 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The report highlights various financial and operational metrics, such as Quality of …

Mira Pharmaceuticals Inc (MIRA) Income Statement

This article provides the quarterly and annual income statements for Mira Pharmaceuticals Inc (MIRA), offering detailed financial data on total revenue, operating expenses, R&D expenses, operating profit, and net income. It includes historical data from FY2021Q1 to FY2026Q1, highlighting key financial metrics and year-over-year …

Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Mira Pharmaceuticals Inc (MIRA) dividends and stock splits, noting that no dividend data is available and zero dividends have been distributed in the past five years. It also includes current stock information, showing MIRA trading at $0.882 with …

Emira Property Fund Ltd. Revenue Breakdown – JSE:EMI

MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL

The article provides a financial overview of MIRA Pharmaceuticals, Inc. (A3EQWL) on the Lang & Schwarz Exchange, detailing available fundamental and statistical data such as overview, statements, statistics, dividends, earnings, and segments. It specifically highlights the company's revenue breakdown by source and country. The …

Mirae Asset Securities Shares Tumble Despite Record Profit Forecast… Is SpaceX Becoming a Liability?

Scotts Miracle-Gro Company (The) Revenue Breakdown – NYSE:SMG

Scotts Miracle Gro (SMG) Stock May Sit Below Fair Value On A 54% Five Year Slump

Scotts Miracle-Gro (SMG) stock has experienced a 54.4% decline over the past five years, despite a 13.6% gain year-to-date. A Discounted Cash Flow (DCF) model suggests the stock is currently undervalued by about 17.3%, trading at a discount to its intrinsic value of $81.68 …

MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:-0.046

Mira Pharmaceuticals Inc (MIRA) closed at $0.882, down 4.97% on July 24th, 2026. The company, a clinical-stage pharmaceutical firm, focuses on developing therapeutics for neurological, neuropsychiatric, and metabolic disorders, including Ketamir-2 and SKNY-1 in its pipeline. Despite strong fundamentals and high growth potential, the …